Niu Pu , Xitong Bo , Haimin Lu, Fuxiang Chen, Yilong Zhou, Qiong Cheng
{"title":"FOSL1:肿瘤-神经相互作用的核心调控枢纽及其临床转化前景。","authors":"Niu Pu , Xitong Bo , Haimin Lu, Fuxiang Chen, Yilong Zhou, Qiong Cheng","doi":"10.1016/j.intimp.2025.115645","DOIUrl":null,"url":null,"abstract":"<div><div>As a core AP-1 transcription factor, FOS like-1 (FOSL1) drives cell proliferation, differentiation, transformation, and tumorigenesis by regulating downstream targets via heterodimer formation. Pan-cancer analyses confirm its characteristic overexpression in solid tumors, with expression levels strongly correlating with tumor invasiveness and metastasis. Emerging evidence highlights tumor-nerve crosstalk in the tumor microenvironment (TME) as a key driver of progression, and recent studies identify FOSL1 as a central regulatory hub linking tumors and the nervous system. It modulates tumor-neural interactions through mechanisms that include Schwann cell reprogramming, chemokine network construction, axon orientation regulation, synaptic connection modulation, and immune-neuro-tumor synergy, thereby promoting neural remodeling, invasion, metastasis, and TME reprogramming. Elucidating FOSL1's multidimensional regulation of tumor-nerve crosstalk not only offers new insights into tumor neural dependency but also establishes a theoretical basis for developing FOSL1-based diagnostic markers, prognostic tools, and novel targeted therapies, with substantial clinical translational potential.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"166 ","pages":"Article 115645"},"PeriodicalIF":4.7000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FOSL1: The core regulatory hub of tumor-neural interactions and its clinical translational prospects\",\"authors\":\"Niu Pu , Xitong Bo , Haimin Lu, Fuxiang Chen, Yilong Zhou, Qiong Cheng\",\"doi\":\"10.1016/j.intimp.2025.115645\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>As a core AP-1 transcription factor, FOS like-1 (FOSL1) drives cell proliferation, differentiation, transformation, and tumorigenesis by regulating downstream targets via heterodimer formation. Pan-cancer analyses confirm its characteristic overexpression in solid tumors, with expression levels strongly correlating with tumor invasiveness and metastasis. Emerging evidence highlights tumor-nerve crosstalk in the tumor microenvironment (TME) as a key driver of progression, and recent studies identify FOSL1 as a central regulatory hub linking tumors and the nervous system. It modulates tumor-neural interactions through mechanisms that include Schwann cell reprogramming, chemokine network construction, axon orientation regulation, synaptic connection modulation, and immune-neuro-tumor synergy, thereby promoting neural remodeling, invasion, metastasis, and TME reprogramming. Elucidating FOSL1's multidimensional regulation of tumor-nerve crosstalk not only offers new insights into tumor neural dependency but also establishes a theoretical basis for developing FOSL1-based diagnostic markers, prognostic tools, and novel targeted therapies, with substantial clinical translational potential.</div></div>\",\"PeriodicalId\":13859,\"journal\":{\"name\":\"International immunopharmacology\",\"volume\":\"166 \",\"pages\":\"Article 115645\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International immunopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1567576925016364\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925016364","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
FOSL1: The core regulatory hub of tumor-neural interactions and its clinical translational prospects
As a core AP-1 transcription factor, FOS like-1 (FOSL1) drives cell proliferation, differentiation, transformation, and tumorigenesis by regulating downstream targets via heterodimer formation. Pan-cancer analyses confirm its characteristic overexpression in solid tumors, with expression levels strongly correlating with tumor invasiveness and metastasis. Emerging evidence highlights tumor-nerve crosstalk in the tumor microenvironment (TME) as a key driver of progression, and recent studies identify FOSL1 as a central regulatory hub linking tumors and the nervous system. It modulates tumor-neural interactions through mechanisms that include Schwann cell reprogramming, chemokine network construction, axon orientation regulation, synaptic connection modulation, and immune-neuro-tumor synergy, thereby promoting neural remodeling, invasion, metastasis, and TME reprogramming. Elucidating FOSL1's multidimensional regulation of tumor-nerve crosstalk not only offers new insights into tumor neural dependency but also establishes a theoretical basis for developing FOSL1-based diagnostic markers, prognostic tools, and novel targeted therapies, with substantial clinical translational potential.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.